Dr. Fordyce brings more than 15 years’ experience leading teams in drug discovery, development, clinical translation, and commercialization of new treatments.
Before founding Vera, Fordyce was the founder and CEO of gene-editing company Trucode Gene Repair, Inc., having previously served as an entrepreneur in residence at Kleiner Perkins Caufield and Byers.
Earlier in his career, Fordyce served as Senior Director of clinical research at Gilead Sciences, Inc., where he contributed to seven new drug approvals and served as project lead for Gilead’s TAF/GENVOYA development program.
With subspecialty training in infectious disease from Columbia University Vagelos College of Physicians and Surgeons, Fordyce was previously Chief Resident at NYU Bellevue and spent two years as a translational research fellow at Rockefeller University.
Fordyce currently serves on the Board of Directors of the Albert and Mary Lasker Foundation. He received his BA from Harvard University and his MD from Harvard Medical School.
What is Marshall Fordyce's net worth?
The estimated net worth of Marshall Fordyce is at least $9.99 million as of February 23rd, 2026. Dr. Fordyce owns 257,163 shares of Vera Therapeutics stock worth more than $9,993,354 as of March 29th. This net worth approximation does not reflect any other investments that Dr. Fordyce may own. Learn More about Marshall Fordyce's net worth.
How do I contact Marshall Fordyce?
Has Marshall Fordyce been buying or selling shares of Vera Therapeutics?
During the last ninety days, Marshall Fordyce has sold $710,511.50 in shares of Vera Therapeutics stock. Most recently, Marshall Fordyce sold 16,925 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a transaction totalling $710,511.50. Following the completion of the sale, the chief executive officer now directly owns 257,163 shares of the company's stock, valued at $10,795,702.74. Learn More on Marshall Fordyce's trading history.
Who are Vera Therapeutics' active insiders?
Vera Therapeutics' insider roster includes Robert Brenner (Insider), Patrick Enright (Director), Marshall Fordyce (Founder), Marshall Fordyce (CEO and Founder), Sean Grant (CFO), David Johnson (COO), Maha Katabi (Director), Beth Seidenberg (Director), Laurence Skelton (Insider), William Turner (Insider), and Joseph Young (CAO). Learn More on Vera Therapeutics' active insiders.
Are insiders buying or selling shares of Vera Therapeutics?
In the last year, Vera Therapeutics insiders bought shares 3 times. They purchased a total of 255,882 shares worth more than $5,527,583.36. In the last year, insiders at the sold shares 8 times. They sold a total of 48,490 shares worth more than $1,841,810.20. The most recent insider tranaction occured on February, 23rd when insider Robert Brenner sold 2,151 shares worth more than $90,298.98. Insiders at Vera Therapeutics own 16.3% of the company.
Learn More about insider trades at Vera Therapeutics. Information on this page was last updated on 2/23/2026.
